-
1.发明公开POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER 有权多环的吲唑衍生物及其作为ERK抑制剂用于治疗癌症的用途
公开(公告)号：EP2155722A1
公开(公告)日：2010-02-24
申请号：EP08768067.4
申请日：2008-06-04
申请人： Schering Corporation
发明人： COOPER, Alan , DENG, Yongqi , SHIPPS, Gerald, W., Jr. , SHIH, Neng-Yang , ZHU, Hugh , KELLY, Joseph , DOLL, Ronald , NAN, Yang , DESAI, Jagdish , WANG, James , PALIWAL, Sunil , TSUI, Hon-Chung , BOGA, Sobhana, Babu , ALHASSAN, Abdul-Basit , GAO, Xiaolei , ZHU, Liang , PATEL, Mehul
IPC分类号： C07D401/14 , C07D403/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D491/056 , A61K31/4245 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号： C07D401/14 , C07D403/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D491/056
摘要： Disclosed are the ERK inhibitors of formula 1.0: (Chemical formula should be inserted here as it appears on abstract in paper form) and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
-
公开(公告)号：EP1984331B1
公开(公告)日：2010-10-20
申请号：EP07750497.5
申请日：2007-02-13
申请人： Schering Corporation
发明人： DENG, Yongqi , SHIPPS, Gerald, W., Jr. , COOPER, Alan , NAN, Yang , WANG, Tong , SIDDIQUI, M., Arshad , ZHU, Hugh , SUN, Robert , KELLY, Joseph , DOLL, Ronald , DESAI, Jagdish , WANG, James , DONG, Youhao , MADISON, Vincent, S. , XIAO, Li , HRUZA, Alan , SHIH, Neng-yang
IPC分类号： C07D207/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/08 , A61K31/4025 , A61P35/00
CPC分类号： C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).
-
公开(公告)号：EP1966151A1
公开(公告)日：2008-09-10
申请号：EP06845064.2
申请日：2006-12-11
申请人： Schering Corporation
发明人： COOPER, Alan , DENG, Yongqi , SHIPPS, Gerald, W., Jr. , SHIH, Neng-yang , ZHU, Hugh , SUN, Robert , KELLY, Joseph , DOLL, Ronald , NAN, Yang , WANG, Tong , DESAI, Jagdish , WANG, James , DONG, Youhao , MADISON, Vincent, S. , XIAO, Li , HRUZA, Alan , SIDDIQUI, M., Arshad , SAMATAR, Ahmed , PALIWAL, Sunil , TSUI, Hon-Chung , CELEBI, Azim, A. , WU, Yiji , BOGA, Sobhana, Babu
IPC分类号： C07D231/56 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61K31/506 , A61K31/427 , A61K31/428 , A61K31/496 , A61P35/00 , C07D417/14 , C07D403/14
CPC分类号： C07D405/14 , C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
-
公开(公告)号：EP1966151B1
公开(公告)日：2011-10-05
申请号：EP06845064.2
申请日：2006-12-11
申请人： Schering Corporation
发明人： COOPER, Alan , DENG, Yongqi , SHIPPS, Gerald, W., Jr. , SHIH, Neng-yang , ZHU, Hugh , SUN, Robert , KELLY, Joseph , DOLL, Ronald , NAN, Yang , WANG, Tong , DESAI, Jagdish , WANG, James , DONG, Youhao , MADISON, Vincent, S. , XIAO, Li , HRUZA, Alan , SIDDIQUI, M., Arshad , SAMATAR, Ahmed , PALIWAL, Sunil , TSUI, Hon-Chung , CELEBI, Azim, A. , WU, Yiji , BOGA, Sobhana, Babu
IPC分类号： C07D231/56 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61K31/506 , A61K31/427 , A61K31/428 , A61K31/496 , A61P35/00 , C07D417/14 , C07D403/14
CPC分类号： C07D405/14 , C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要： Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
-
公开(公告)号：EP1984331A1
公开(公告)日：2008-10-29
申请号：EP07750497.5
申请日：2007-02-13
申请人： Schering Corporation
发明人： DENG, Yongqi , SHIPPS, Gerald, W., Jr. , COOPER, Alan , NAN, Yang , WANG, Tong , SIDDIQUI, M., Arshad , ZHU, Hugh , SUN, Robert , KELLY, Joseph , DOLL, Ronald , DESAI, Jagdish , WANG, James , DONG, Youhao , MADISON, Vincent, S. , XIAO, Li , HRUZA, Alan , SHIH, Neng-yang
IPC分类号： C07D207/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D487/08 , A61K31/4025 , A61P35/00
CPC分类号： C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要： Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).
-
-
-
-
搜索结果
5 条记录 (耗时 0.017 秒)
